Flash FinanceUS
Market closed S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · NEKTAR THERAPEUTICS (NKTR)

Nektar Therapeutics enters quiet period ahead of alopecia areata Phase 2b data

Neutral Impact 2 of 5 other Written later

Nektar Therapeutics said it entered a quiet period starting September 8, 2026, until it publicly announces 24-week off-treatment follow-up data from its Phase 2b REZOLVE-AA study of rezpegaldesleukin in severe-to-very-severe alopecia areata. The company said the quiet period is consistent with its prior quiet periods for the REZOLVE studies, so the filing signals timing of a future data release rather than results themselves.

Key points

  • Quiet period began September 8, 2026 and runs until the data announcement.
  • Data to be disclosed is from the 24-week off-treatment follow-up of the Phase 2b REZOLVE-AA study.
  • Study covers rezpegaldesleukin in patients with severe-to-very-severe alopecia areata.
  • Company says the quiet period matches its earlier REZOLVE study practices.

The filing

CompanyNEKTAR THERAPEUTICS (NKTR)
Form8-K, current report
Filed with the SECSep 8, 2026, 4:10 PM ET
Accession number0001213900-26-098042

Items reported: 7.01 Regulation FD Disclosure

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:29 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on September 08, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.